Additionally, adoptive cell therapy using GPC3-targeted chimeric antigen receptor macrophages (CAR-Ms) demonstrates promise through antigen-specific phagocytosis, tumor clearance, and M1 phenotype adoption in HCC models (623). This evidence concerns the gene GPC3 and hepatocellular carcinoma.